Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 mill...











            

                Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.






    
        
            May 09, 2025 09:15 ET
        

        
             | Source:
            

                Celularity Inc.
            

        
    

    

    

    





        
FLORHAM PARK, N.J., May  09, 2025  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024.  “We built momentum through 2024 and ended the year with a strong finish, as reflected in higher net revenues from the sale of our commercial-stage advanced biomaterial products," said Dr. Robert Hariri, M.D., Ph.D., CEO and Chairman. “Sales growth was notably strong for our Biovance® product line, which we believe will continue to contribute to an improving revenue outlook for the next several quarters. We were also extremely pleased to receive recommendation letters from the U.S. Food and Drug Administration Tissue Reference Group regarding important additions to our portfolio of human placental-derived advanced biomaterial products, which serves as a testament to our commitment to innovate in the wound care sector along with our development of next-generation 510(k) products. At the same time, we continued to act opportunistically and explore opportunities in the rapidly evolving landscape of cellular and regenerative medicine. We believe Celularity will gain additional momentum in 2025 as we leverage our unique business model and world-class technical infrastructure and human capital.”  Highlights of Full Year 2024 Operating and Financial Results  Net Revenues  Net revenues for the year ended December 31, 2024, was $54.2 million, an increase of $31.4 million, or 138.1%, compared to the prior year period. This growth was primarily due to a $22.2 million increase in product sales in wound care applications, which increased 168.7% over the prior year.  Operating Expenses  Total operating expenses for the year ended December 31, 2024, were $92.6 million, a decrease of $122.5 million, or 57.0%, compared to 2023. The decrease in operating expenses is attributable to the absence of goodwill and in-process research and development, or IPR&D, impairments in 2024. Loss from operations for the year ending December 31, 2024, was $38.4 million, a decrease of $153.9 million, or 80.1%, compared to the previous year, driven by higher revenue and lower operating expenses which improved our gross margin.  Results of OperationsComparison of Year Ended December 31, 2024 to December 31, 2023 (in thousands) Year Ended December 31,     Percent   2024  2023  Change  Change Revenues:            Product sales, net $35,336  $13,149  $22,187   168.7% Services  5,140   5,441   (301)   (5.5)% License, royalty and other  13,744   4,181   9,563   228.7% Total revenues  54,220   22,771   31,449   138.1% Operating expenses:                Cost of revenues (excluding amortization of acquired intangible assets)                Product sales  4,924   8,628   (3,704)   (42.9)% Services  1,172   1,650   (478)   (29.0)% License, royalty and other  8,893   5,738   3,155   55.0% Research and development  17,386   30,465   (13,079)   (42.9)% Selling, general and administrative  58,643   50,576   8,067   16.0% Change in fair value of contingent consideration liability  (193)   (104,339)   104,146   (99.8)% Goodwill impairment  —   112,347   (112,347)   (100.0)% IPR&D impairment  —   107,800   (107,800)   (100.0)% Amortization of acquired intangible assets  1,753   2,193   (440)   (20.1)% Total operating expenses  92,578   215,058   (122,480)   (57.0)% Loss from operations $(38,358)  $(192,287)  $153,929   (80.1)%  CELULARITY INC.CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share amounts)          December 31,   2024  2023 Assets      Current assets:        Cash and cash equivalents $738  $227 Accounts receivable, net of allowance of $6,294 and $5,837 as of December 31, 2024 and 2023, respectively  13,557   10,046 Notes receivable  —   2,072 Inventory  5,409   5,753 Prepaid expenses and other current assets  857   1,695 Total current assets  20,561   19,793 Property and equipment, net  61,600   67,828 Goodwill  7,347   7,347 Intangible assets, net  9,248   11,001 Right-of-use assets - operating leases  10,830   10,990 Restricted cash  10,239   9,936 Inventory, net of current portion  12,587   16,657 Other long-term assets  270   337 Total assets $132,682  $143,889 Liabilities and Stockholders’ Equity        Current liabilities:        Accounts payable $23,296  $14,144 Accrued expenses and other current liabilities  19,842   7,580 Accrued R&D software  —   3,500 Acquisition-related contingent consideration  650   — Short-term debt - unaffiliated (includes debt measured at fair value of $2,485 and $17,223 as of December 31, 2024 and 2023, respectively)  2,485   19,331 Short-term debt - related parties  3,876   19,909          Deferred revenue  3,531   2,834 Total current liabilities  53,680   67,298 Deferred revenue, net of current portion  2,724   3,186 Acquisition-related contingent consideration, net of current portion  1,413   1,606 Long-term debt - related parties  35,927   — Long-term lease liabilities  26,548   26,177 Warrant liabilities  3,264   4,359 Deferred income tax liabilities  9   9 Other liabilities  280   294 Total liabilities  123,845   102,929 Commitments and Contingencies (Note 12)        Stockholders’ equity:        Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023  —   — Common stock, $0.0001 par value, 730,000,000 shares authorized, 22,546,671 and 19,378,192 issued and outstanding as of December 31, 2024 and 2023, respectively  2   19 Additional paid-in capital  908,523   882,732 Accumulated deficit  (899,683)   (841,791) Accumulated other comprehensive loss  (5)   — Total stockholders’ equity  8,837   40,960 Total liabilities and stockholders’ equity $132,682  $143,889  About Celularity  Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.  For more information, visit www.celularity.com.  Forward Looking StatementsThis press release includes “forward-looking statements” (as defined under Federal securities laws).These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,” and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.  Contact   Carlos RamirezSenior Vice President, Celularity Inc.Carlos.ramirez@celularity.com  
            

CELU

Celularity Announces Full Year 2024 Operating and Financial Results

Celularity's 2024 net revenues reached $54.2 million, up 138.1%.
Product sales in wound care surged 168.7%, boosting growth.
Operating expenses decreased 57% due to fewer impairments.
CEO notes strong momentum and positive outlook for 2025.
FDA recommendations for new products enhance competitiveness.

Celularity Announces Full Year 2024 Operating and Financial Results

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News